Literature DB >> 7878022

Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms.

L Buscail1, J P Estève, N Saint-Laurent, V Bertrand, T Reisine, A M O'Carroll, G I Bell, A V Schally, N Vaysse, C Susini.   

Abstract

Effects of the stable somatostatin analogue RC-160 on cell proliferation, tyrosine phosphatase activity, and intracellular calcium concentration were investigated in CHO cells expressing the five somatostatin receptor subtypes SSTR1 to -5. Binding experiments were performed on crude membranes by using [125I-labeled Tyr11] somatostatin-14; RC-160 exhibited moderate-to-high affinities for SSTR2, -3, and -5 (IC50, 0.17, 0.1 and 21 nM, respectively) and low affinity for SSTR1 and -4 (IC50, 200 and 620 nM, respectively). Cell proliferation was induced in CHO cells by 10% (vol/vol) fetal calf serum, 1 microM insulin, or 0.1 microM cholecystokinin (CCK)-8; RC-160 inhibited serum-induced proliferation of CHO cells expressing SSTR2 and SSTR5 (EC50, 53 and 150 pM, respectively) but had no effect on growth of cells expressing SSTR1, -3, or -4. In SSTR2-expressing cells, orthovanadate suppressed the growth inhibitory effect of RC-160. This analogue inhibited insulin-induced proliferation and rapidly stimulated the activity of a tyrosine phosphatase in only this cellular clone. This latter effect was observed at doses of RC-160 (EC50, 4.6 pM) similar to those required to inhibit growth (EC50, 53 pM) and binding to the receptor (IC50, 170 pM), implicating tyrosine phosphatase as a transducer of the growth inhibition signal in SSTR2-expressing cells. In SSTR5-expressing cells, the phosphatase pathway was not involved in the inhibitory effect of RC-160 on cell growth, since this action was not influenced by tyrosine and serine/threonine phosphatase inhibitors. In addition, in SSTR5-expressing cells, RC-160 inhibited CCK-stimulated intracellular calcium mobilization at doses (EC50, 0.35 nM) similar to those necessary to inhibit somatostatin-14 binding (IC50, 21 nM) and CCK-induced cell proliferation (EC50, 1.1 nM). This suggests that the inositol phospholipid/calcium pathway could be involved in the antiproliferative effect of RC-160 mediated by SSTR5 in these cells. RC-160 had no effect on the basal or carbachol-stimulated calcium concentration in cells expressing SSTR1 to -4. Thus, we conclude that SSTR2 and SSTR5 bind RC-160 with high affinity and mediate the RC-160-induced inhibition of cell growth by distinct mechanisms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7878022      PMCID: PMC42563          DOI: 10.1073/pnas.92.5.1580

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

Review 1.  Protein tyrosine phosphatases.

Authors:  K M Walton; J E Dixon
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

2.  All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase.

Authors:  Y C Patel; M T Greenwood; A Warszynska; R Panetta; C B Srikant
Journal:  Biochem Biophys Res Commun       Date:  1994-01-28       Impact factor: 3.575

3.  Characterization of cloned somatostatin receptors SSTR4 and SSTR5.

Authors:  K Raynor; A M O'Carroll; H Kong; K Yasuda; L C Mahan; G I Bell; T Reisine
Journal:  Mol Pharmacol       Date:  1993-08       Impact factor: 4.436

4.  Somatostatin inhibition of phosphoinositides turnover in isolated rat acinar pancreatic cells: interaction with bombesin.

Authors:  C Linard; F Reyl-Desmars; M J Lewin
Journal:  Regul Pept       Date:  1992-10-13

5.  Effects of okadaic acid indicate a role for dephosphorylation in pancreatic stimulus-secretion coupling.

Authors:  A C Wagner; M J Wishart; D I Yule; J A Williams
Journal:  Am J Physiol       Date:  1992-12

6.  Inhibition of gastrin-induced proliferation of AR4-2J cells by calcium channel antagonists.

Authors:  V Bertrand; M J Bastié; N Vaysse; L Pradayrol
Journal:  Int J Cancer       Date:  1994-02-01       Impact factor: 7.396

7.  Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase.

Authors:  K Yasuda; S Rens-Domiano; C D Breder; S F Law; C B Saper; T Reisine; G I Bell
Journal:  J Biol Chem       Date:  1992-10-05       Impact factor: 5.157

8.  Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28.

Authors:  A M O'Carroll; S J Lolait; M König; L C Mahan
Journal:  Mol Pharmacol       Date:  1992-12       Impact factor: 4.436

9.  Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4.

Authors:  Y Xu; J Song; J F Bruno; M Berelowitz
Journal:  Biochem Biophys Res Commun       Date:  1993-06-15       Impact factor: 3.575

10.  Somatostatin receptor subtype gene expression in human and rodent tumors.

Authors:  P A Eden; J E Taylor
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

View more
  53 in total

Review 1.  The therapeutic value of somatostatin and its analogues.

Authors:  S Farooqi; J S Bevan; M C Sheppard; J A Wass
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

2.  SST3-selective potent peptidic somatostatin receptor antagonists.

Authors:  J C Reubi; J C Schaer; S Wenger; C Hoeger; J Erchegyi; B Waser; J Rivier
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop.

Authors:  Erika Peverelli; Andrea G Lania; Giovanna Mantovani; Paolo Beck-Peccoz; Anna Spada
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

4.  Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation.

Authors:  Geraldine Ferjoux; Frederic Lopez; Jean-Pierre Esteve; Audrey Ferrand; Eric Vivier; Frederic Vely; Nathalie Saint-Laurent; Lucien Pradayrol; Louis Buscail; Christiane Susini
Journal:  Mol Biol Cell       Date:  2003-07-11       Impact factor: 4.138

5.  A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.

Authors:  Cihangir Erem; Arif Hacihasanoglu; Ahmet Sari; Halil Onder Ersöz; Kubilay Ukinç; Sami Fidan
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

6.  Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation.

Authors:  R Colucci; C Blandizzi; N Ghisu; T Florio; M Del Tacca
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

Review 7.  Somatostatin.

Authors:  T Reisine
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

8.  Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.

Authors:  P Cordelier; J P Estève; C Bousquet; N Delesque; A M O'Carroll; A V Schally; N Vaysse; C Susini; L Buscail
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 9.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

10.  Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

Authors:  A Nagy; A V Schally; G Halmos; P Armatis; R Z Cai; V Csernus; M Kovács; M Koppán; K Szepesházi; Z Kahán
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.